Shares of Mallinckrodt PLC (NYSE:MNK) have been given a consensus recommendation of “Hold” by the twenty-two brokerages that are presently covering the firm, MarketBeat reports. Three analysts have rated the stock with a sell recommendation, fourteen have given a hold recommendation and five have given a buy recommendation to the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $27.44.
A number of research analysts have commented on the stock. SunTrust Banks raised their price target on shares of Mallinckrodt to $21.00 and gave the stock a “hold” rating in a research note on Tuesday, June 19th. Stifel Nicolaus raised their price target on shares of Mallinckrodt from $15.00 to $18.00 and gave the stock a “hold” rating in a research note on Monday, June 18th. Oppenheimer restated a “hold” rating on shares of Mallinckrodt in a research note on Tuesday, February 27th. Cantor Fitzgerald set a $42.00 price target on shares of Mallinckrodt and gave the stock a “buy” rating in a research note on Tuesday, February 27th. Finally, Canaccord Genuity set a $20.00 price target on shares of Mallinckrodt and gave the stock a “hold” rating in a research note on Tuesday, March 6th.
Get Mallinckrodt alerts:
In other Mallinckrodt news, insider Mark Trudeau acquired 3,000 shares of Mallinckrodt stock in a transaction on Wednesday, May 16th. The shares were purchased at an average cost of $15.54 per share, with a total value of $46,620.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider James E. Flynn sold 312,928 shares of the firm’s stock in a transaction that occurred on Wednesday, May 9th. The shares were sold at an average price of $13.39, for a total transaction of $4,190,105.92. The disclosure for this sale can be found here. Company insiders own 1.80% of the company’s stock.
Hedge funds have recently made changes to their positions in the business. Victory Capital Management Inc. bought a new position in Mallinckrodt in the first quarter valued at approximately $104,000. Amundi Pioneer Asset Management Inc. bought a new position in Mallinckrodt in the fourth quarter valued at approximately $190,000. Sciencast Management LP bought a new position in Mallinckrodt in the fourth quarter valued at approximately $210,000. Bronfman E.L. Rothschild L.P. boosted its stake in Mallinckrodt by 11,188.0% in the first quarter. Bronfman E.L. Rothschild L.P. now owns 10,385 shares of the company’s stock valued at $150,000 after acquiring an additional 10,293 shares during the last quarter. Finally, Virginia Retirement Systems ET AL bought a new position in Mallinckrodt in the first quarter valued at approximately $175,000.
Mallinckrodt traded down $0.17, reaching $19.27, during midday trading on Tuesday, according to MarketBeat. 11,539,671 shares of the company’s stock were exchanged, compared to its average volume of 2,583,143. The stock has a market cap of $1.62 billion, a price-to-earnings ratio of 2.57, a P/E/G ratio of 0.32 and a beta of 1.21. The company has a quick ratio of 1.90, a current ratio of 2.10 and a debt-to-equity ratio of 1.00. Mallinckrodt has a one year low of $11.65 and a one year high of $49.12.
Mallinckrodt (NYSE:MNK) last announced its quarterly earnings results on Tuesday, May 8th. The company reported $1.31 EPS for the quarter, topping analysts’ consensus estimates of $1.08 by $0.23. The firm had revenue of $572.60 million during the quarter, compared to analysts’ expectations of $568.78 million. Mallinckrodt had a net margin of 57.56% and a return on equity of 11.59%. The company’s revenue for the quarter was up 2.2% compared to the same quarter last year. During the same quarter last year, the company earned $1.04 earnings per share. equities research analysts expect that Mallinckrodt will post 6.23 EPS for the current fiscal year.
Mallinckrodt Company Profile
Mallinckrodt public limited company develops, manufactures, markets, and distributes branded pharmaceutical products in Canada and the European Union, as well as in Latin American, the Middle Eastern, African, and the Asia-Pacific regions. The company markets branded pharmaceutical products for autoimmune and rare diseases in the specialty areas of neurology, rheumatology, nephrology, ophthalmology, and pulmonology; and immunotherapy and neonatal respiratory critical care therapies, as well as analgesics and gastrointestinal products.